Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pfizer Inc. (PFE) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, with AI‑powered tools to help interpret complex documents. As a large issuer in the pharmaceutical preparation manufacturing industry, Pfizer files a wide range of reports that are important for understanding its operations, capital structure and risk profile.
Investors can review Form 8‑K current reports that describe material events such as financial results, public offerings of notes, acquisitions and guidance updates. Recent 8‑K filings detail second‑ and third‑quarter 2025 financial results, full‑year 2025 and 2026 revenue and adjusted EPS guidance, a multi‑tranche public offering of senior notes with maturities extending to 2065, and the completed acquisition of Metsera, a company developing GLP‑1‑based obesity therapies.
Pfizer’s 8‑Ks also reference shelf registration statements and supplemental indentures governing its debt securities, as well as underwriting and pricing agreements with major investment banks. These filings help users track how Pfizer raises long‑term capital and manages its balance sheet. Other 8‑Ks furnish press releases under Regulation FD, including guidance updates that outline expected revenue contributions from COVID‑19 products and the impact of loss of exclusivity on certain medicines.
On Stock Titan, AI‑generated summaries highlight the key points of lengthy filings, explaining in plain language what new debt offerings, acquisitions, guidance changes or other events may mean for the company. Users can quickly identify which exhibits relate to indentures, legal opinions or merger agreements, and can follow how Pfizer’s financing activities and strategic transactions evolve over time.
In addition to 8‑Ks, this page links to Pfizer’s other core SEC reports, such as annual and quarterly filings, where available. Together, these documents provide a regulatory record of Pfizer’s financial performance, risk factors, capital markets activity and major corporate actions, with AI assistance to make the information more accessible.
de Germay Alexandre reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Executive Vice President Alexandre de Germay received a grant of 194,883 stock appreciation rights on Pfizer common stock. These rights were awarded at no purchase price and are classified as a derivative security. According to the terms, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.
Pfizer Inc. senior vice president and controller Jennifer B. Damico reported a tax-related share disposition. On February 27, 2026, 655 shares of Pfizer common stock at $27.65 per share were withheld to cover tax obligations upon the vesting of restricted stock units, leaving her with 12,041 directly owned shares.
Pfizer Executive Vice President Payal Sahni reported transactions tied to stock appreciation rights. She exercised stock appreciation rights for 56,888 shares of common stock on
To cover related tax obligations and exercise costs, 1,083 shares at
Pfizer Inc. Executive Vice President Douglas M. Lankler settled stock-based compensation tied to stock appreciation rights on February 25, 2026. He exercised 122,907 stock appreciation rights, receiving the same number of Pfizer common shares at a reference price of $33.82 per share.
To cover related tax obligations and exercise price, 2,198 shares were withheld at $27.09 per share and 116,811 shares were withheld at $26.92 per share. Following these transactions, he held 163,177 shares of Pfizer common stock directly and 2,083 shares indirectly through a Rule 16b-3 plan.
Pfizer Inc. senior vice president and controller Jennifer B. D'Amico reported transactions tied to stock appreciation rights (SARs). On earn-out of these SARs, she acquired 17,558 shares of Pfizer common stock through an exercise or conversion at a reference price of $33.82 per share. In connection with the earn-out, 361 shares at $27.09 per share and 16,687 shares at $26.92 per share were withheld to cover tax obligations and the exercise price. After these tax-withholding dispositions, she directly owned 12,696 shares of Pfizer common stock. These moves reflect equity compensation settlement rather than open-market buying or selling.
Pfizer Inc. Chairman & CEO Albert Bourla reported multiple equity transactions involving stock appreciation rights and common shares. On February 25, 2026, he exercised 491,626 stock appreciation rights, which were settled in an equal number of Pfizer common shares at
According to the footnotes, this earn-out included dividend equivalents and used a 20-day average of Pfizer’s closing prices to determine settlement. To cover the exercise price and related tax obligations, 467,241 and 8,303 common shares were withheld at prices of
After these transactions, Bourla directly owned 388,671 Pfizer common shares and indirectly held 6,003 additional shares through a Rule 16b-3 plan. The filing reflects an exercise and settlement of incentive awards with associated share withholding, rather than discretionary market trading.
Pfizer Inc executive Lidia Fonseca reported derivative and related share transactions tied to stock appreciation rights (SARs). On February 25, 2026, she exercised 56,888 SARs, receiving 56,888 shares of Pfizer common stock at an exercise price of $33.82 per share.
To cover taxes and exercise costs from this earn-out, 1,058 shares and 54,066 shares of common stock were withheld in tax-withholding dispositions at prices of $27.09 and $26.92 per share, respectively. After these transactions, her directly owned Pfizer common stock position was 46,455 shares, and the exercised SARs balance was reduced to zero. Footnotes specify these events arise from the earn-out and settlement terms of the SARs, which use a 20-day average closing price of Pfizer common stock.
Pfizer Inc. Executive Vice President Michael McDermott reported several equity-related transactions involving Pfizer common stock and stock appreciation rights. On February 25, 2026, he exercised 37,925 stock appreciation rights, which were settled in Pfizer common stock as part of an earn-out of these awards, including dividend equivalents. This exercise generated 37,925 common shares at a reference price of $33.82 per share, increasing his direct common stock holdings.
In connection with this earn-out and related restricted stock unit vesting, Pfizer withheld shares to cover tax obligations and exercise price. These withholding dispositions of common stock totaled 3,503 shares on February 26, 2026 at $27.10, plus 679 shares and 36,044 shares on February 25, 2026 at prices of $27.09 and $26.92 per share, respectively. After these transactions, McDermott directly held 74,308 Pfizer common shares, with the derivative stock appreciation rights position reported as fully settled.
Pfizer Inc. President of R&D Christoffel Boshoff reported equity award activity involving Pfizer common stock. On
On the same date, 6,833 shares were disposed of at
Pfizer Inc. provides a comprehensive annual overview of its global biopharmaceutical business, strategy, risks and intellectual property. The company operates mainly through its Biopharma segment, supported by contract manufacturing (PC1), while winding down Pfizer Ignite.
Pfizer reports $25.5 billion of 2025 revenue from operations outside the U.S., representing 41% of total revenues, with China and Japan highlighted as key markets. It details major products and patent expirations through 2041, emphasizes oncology, vaccines, cardiometabolic and immunology R&D, and outlines 2026 priorities: maximizing key transactions, delivering critical R&D milestones, investing for post‑2028 growth, and scaling AI across the business.